Brief: Pharnext amends protocol of international pivotal phase 3 trials of PXT3003
18/09/2017 17:01
Sept 18 (Reuters) - PHARNEXT SAS PHARN.PA :
* AMENDS PROTOCOL OF INTERNATIONAL PIVOTAL PHASE 3 TRIALS
OF PXT3003 FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
* AMENDMENT TO ADDRESS A STABILITY ISSUE IN HIGH DOSE
FORMULATION OF PXT3003
Source text for Eikon: ID:nBw90s8DCa
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development